Introduction
============

Acute Myocardial Infarction (Ami) Is One Of The Most Common Causes Of Death Worldwide, And It Is More Common In Persons Of Advancing Age.[@B1] Because Of World Population Ageing, Many Countries Have Attempted To Reduce The Incidence And Mortality Rate Of Ami. The Representative Primary And Secondary Prevention Measures For Cardiovascular Disease Are Smoking Cessation, Weight Reduction, Lowering The Blood Pressure, And Decreasing The Glucose And Cholesterol Levels. In Korea, Like Other Developed Countries, A National Effort Has Resulted In A Decrease In The Overall Incidence Of Ami Over The Last Few Years.[@B2] However, There Is No Significant Change In The incidence of AMI in younger patients.

Previous studies showed an approximately 2 to 10% incidence of AMI in younger patients.[@B3][@B4][@B5] Remarkable changes in lifestyle and diet, and improvement in the socio-economic status have been noted in Korea over decades. These changes have led to obesity, increased levels of blood pressure, glucose, and cholesterol in younger Korean adults. As a result, these patients are in an increased atherothrombotic state.

Because the emerging risk factors, clinical manifestations, and outcomes of acute ST-segment elevation myocardial infarction (STEMI) in younger Korean adults are unclear, this study aims to investigate the clinical profiles of younger STEMI patients through a one-year follow-up.

Subjects and Methods
====================

Korea Acute Myocardial Infarction Registry (KAMIR) is a Korean, prospective, open, observational, multicenter on-line registry of AMI supported by the Korean Society of Cardiology. The collected data were merged with an intention to improve the statistical power. Protocols and details of KAMIR have been published elsewhere.[@B6] The registry protocols were verified and approved by the Institutional Review Board of each participating center. AMI was diagnosed by the characteristic presentation, serial changes on electrocardiogram (ECG) suggesting infarction, and an increase in cardiac enzymes.[@B7] STEMI was defined as a new ST elevation in ≥2 contiguous leads, measuring \>0.2 mV in leads V1-3 or 0.1 mV in all other leads, or a new left branch bundle block on a 12-lead ECG with a concomitant increase in troponin-I or -T.

Study design and patient population
-----------------------------------

From November 2005 to October 2010, 27852 patients with a final diagnosis of AMI were enrolled in the KAMIR. Among them, we selected the patients with STEMI and excluded the patients whose recorded data, including demographic features, angiographic findings, and procedure details, were invalid or incomplete. We divided the patients into two groups according to the age at admission: young age group (under the age of 65 years) and old age group (65 years of age or older).[@B8] Finally, a total of 10177 patients were enrolled in this study.

Study variables
---------------

Demographic data and baseline clinical characteristics including age, gender, body mass index (BMI) at admission, presenting symptoms, classical cardiovascular risk factors {hypertension (HTN), diabetes mellitus (DM), dyslipidemia (DL), smoking status, and family history of coronary heart disease (CHD)}, and other co-morbidities were identified. Initial vital signs including systolic blood pressure, diastolic blood pressure, and heart rate were measured. Obesity was defined as BMI ≥25 kg/m^2^.[@B9] Metabolic syndrome was defined according to the revised National Cholesterol Education Program Adult Treatment Panel III criteria.[@B10] Attending physicians and/or cardiologists evaluated the patients using the Killip classification and also analyzed the electrocardiogram findings in all patients. Blood samples for baseline laboratory tests were collected at admission or before percutaneous coronary intervention (PCI). Also, blood was collected for lipid profile after an overnight fast. The left ventricular ejection fraction (LVEF) was measured by two-dimensional electrocardiography using the biplane Simpson\'s method before discharge.[@B11]

Initial treatment strategy for STEMI included primary PCI, facilitated PCI, thrombolysis, or conservative treatment, which was at the discretion of the attending physicians and/or cardiologists. Primary PCI was defined as emergent PCI performed within 12 hours after admission,[@B12] and/or PCI in patients with continuing ischemic symptoms, cardiogenic shock, and acute severe heart failure, even after 12 hours.[@B13][@B14][@B15] During the index PCI, the interventional cardiologists had made some important decisions about using balloon pre-dilatation and intracoronary stents. Pre-procedure and post-procedure coronary flow in the target vessel was graded according to the classification used in the Thrombolysis In Myocardial Infarction (TIMI) trials.[@B16] All of the patients with STEMI were treated with optimal medications which were recommended by the evidence-based guidelines during hospitalization and after discharge.

Clinical outcomes
-----------------

We analyzed the major adverse cardiac events (MACE) defined as a composite of cardiac death, myocardial infarction (MI), and repeated PCI (target lesion or target vessel revascularization, or non-target vessel revascularization) or coronary bypass graft (CABG). Cardiac death was defined as death due to pump failure, arrhythmia, or mechanical complications including ventricular septal rupture and free wall rupture. Follow-up data were obtained by reviewing the medical records and/or telephone interview of patients. All data were entered into an electronic web-based case-report form.

Statistical analysis
--------------------

For discrete variables, differences were expressed as counts and percentages, and differences between groups were analyzed using the Chi-square test (or Fisher\'s exact) as appropriate. For continuous variables, differences between groups were evaluated using the unpaired t-test or Mann-Whitney rank-sum test. Multivariate Cox regression analyses were performed using all available variables that could be of potential relevance in determining the impact of different age groups on clinical outcomes. In addition, multivariate logistic regression analyses were performed to determine the factors predicting cumulative one-year MACE in the young and old age groups. First, all of the variables such as the initial clinical characteristics, angiographic findings, and procedural findings were analyzed by the univariate logistic regression analysis. From this analysis, we constructed the multivariate logistic regression model using variables that were clinically significant (p\<0.05). Hazard ratios and 95% confidence intervals were identified. All of the analyses were 2-tailed, with clinical significance defined as p\<0.05. Statistical analysis was performed with SPSS 20.0 for Windows (SPSS-PC, Chicago, IL, USA).

Results
=======

Baseline clinical characteristics
---------------------------------

Among the 10177 patients, the young age group included 5281 patients (age, 53±7.8 years) and the old age group included 4896 patients (age, 74.3±6.5 years). Baseline characteristics are listed in [Table 1](#T1){ref-type="table"}. The young age group had a higher proportion of males and a higher incidence of obesity than the old age group, and patients in the young age group complained of typical chest pain more frequently. Smoking, family history, dyslipidemia, and metabolic syndrome were more frequently observed in the young age group than in the old age group (77.3% vs. 47.2%, p\<0.001; 11% vs. 4.6%, p\<0.001; 11.2% vs. 7.7%, p\<0.001; 67.6% vs. 62.9%, p\<0.001). The patients in the young age group were more frequently classified into the Killip class I (78.4% vs. 66.6%, p\<0.001) and had a higher prevalence of sinus rhythm (92% vs. 87.1%, p\<0.001), in comparison with the patients in the old age group.

Baseline laboratory findings
----------------------------

Baseline laboratory findings and echocardiographic findings are listed in [Table 2](#T2){ref-type="table"}. The levels of creatinine kinase-MB (CK-MB), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and LVEF were higher in the young age group (199.3 ng/mL vs. 171.5 ng/mL, p\<0.001; 191.2 mg/dL vs. 178.3 mg/dL, p\<0.001; 145.2 mg/dL vs. 108.1 mg/dL, p\<0.001; 122.8 mg/dL vs. 112.8 mg/dL, p\<0.001; 52% vs. 49.4%, p\<0.001). The levels of creatinine, glucose, high-sensitivity C-reactive protein, and N-terminal pro-B-type natriuretic peptide were lower in the young age group (1.1 mg/dL vs. 1.2 mg/dL, p=0.041; 169.7 mg/dL vs. 173.7 mg/dL, p=0.007; 8.1 mg/dL vs. 10.8 mg/dL, p=0.002; 1001 pg/mL vs. 2834.1 pg/mL, p\<0.001). There were no significant differences in the troponin-I, troponin-T, and high-density lipoprotein cholesterol (HDL-C) between the two groups. The estimated glomerular filtration rate by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation,[@B17] which considers the age and sex, was higher in the young age group (93.7 mL/min/1.73m^2^ vs. 78.5 mL/min/1.73m^2^, p\<0.001).

Treatment modalities for ST-segment elevation myocardial infarction
-------------------------------------------------------------------

There Was No Significant Difference In The Rate Of Undergoing Primary And Facilitated Pci ([Table 3](#T3){ref-type="table"}). While Patients In The Young Age Group Underwent Thrombolysis More Frequently (7.5% Vs. 4.9%, P\<0.001), Patients In The Old Age Group Were More Frequently Treated Conservatively (10.6% Vs. 7.2%, P\<0.001).

Baseline coronary angiographic findings and procedure characteristics
---------------------------------------------------------------------

The young and old age groups showed a similar door-to-balloon time (106.4 min vs. 106.6 min, p=0.847) ([Table 3](#T3){ref-type="table"}). The younger adults had a fewer number of diseased vessels, and a lower percentage of left main (LM) complex disease and American College of Cardiology/American Heart Association (ACC/AHA) lesion type C. In the young age group, the left anterior descending artery was involved more frequently, while the right coronary artery was involved more frequently in the old age group. Shorter, larger, and fewer number of stents were used in young patients (24.4 mm vs. 24.7 mm, p=0.018; 3.5 mm vs. 3.3 mm, p\<0.001; 1.4 vs. 1.5, p=0.002) during the index PCI. Drug-eluting stents, especially sirolimus-eluting stents, were used more frequently in the young age group. Although there was no significant difference in pre-procedure TIMI flow 0, the younger patients had a higher incidence of post-procedure TIMI flow 3.

Comparison of the prescribed medications
----------------------------------------

We compared the prescribed medications at the time of discharge ([Table 4](#T4){ref-type="table"}). The use of aspirin, clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitors, and statin was more frequent in the young age group (98.5% vs. 97.7%, p=0.003; 99.7% vs. 95.9%, p=0.033; 80.1% vs. 74.6%, p\<0.001; 68.9% vs. 63.9%, p\<0.001; 77.2% vs. 73.4%, p\<0.001).

Clinical outcomes
-----------------

[Table 5](#T5){ref-type="table"} shows in-hospital mortality, complications, and cumulative clinical outcomes during the follow-up period. According to our analyses of cumulative clinical outcomes, patients in the young age group stayed in the coronary care unit for a shorter time period (3.2 days vs. 3.9 days, p\<0.001). The old age group had a higher rate of in-hospital death (3.5 % vs. 0.7 %, p\<0.001) compared with the young age group. The rates of one-month, six-month, and twelve-month MACEs were lower in the young age group. The adjusted MACE rates, by Cox regression analyses, at one month and twelve months were not different between the two age groups ([Table 6](#T6){ref-type="table"}). These results were consistent with the adjusted all-cause death rate ([Fig. 1](#F1){ref-type="fig"}).

In the multivariate logistic regression analysis, the presence of multivessel disease, renal insufficiency, and LM complex lesion were independent predictors of MACE at one year after STEMI in younger adults ([Table 7](#T7){ref-type="table"}). On the contrary, complete multivessel revascularization during the index PCI in younger STEMI patients was associated with favorable outcomes.

Discussion
==========

This is the first, large, multicenter, prospective study in younger Korean patients with STEMI. About half of the STEMI patients (52%) were less than 65 years of age. Previous studies have demonstrated that the young age group has a higher proportion of males, smokers, DL, family history, and a lower incidence of HTN and DM than the old age group.[@B3][@B5][@B18][@B19] The results of our study in younger Korean adults were in agreement with those of previous studies in many aspects ([Table 1](#T1){ref-type="table"}). Cigarette smoking was the most common and modifiable cause of AMI in younger patients in our study. Smoking is a major independent risk factor for ischemic heart disease, cerebrovascular disease, and total atherosclerotic cardiovascular disease.[@B20] It is well known that smoking has an adverse effect on serum lipids, and it is associated with insulin resistance,[@B21] enhanced prothrombotic state, elevated fibrinogens, and increased platelet activity.[@B22] The relative benefits of smoking cessation are equivalent in young and old patients.[@B23] Since the rate of smoking in younger STEMI patients is high, it is more important to encourage smoking cessation in patients of the young age group than in those of the old age group.

The other risk factor among younger adults with STEMI was obesity. Obesity has been known to be an independent risk factor for CHD.[@B24] It causes some changes in lipid metabolism, elevation of TG, LDL-C, and lowers the concentration of HDL-C.[@B25] We observed that the incidence of dyslipidemia was higher in younger Korean STEMI patients than in older Korean STEMI patients. Finally, the incidence of metabolic syndrome was higher in younger adults with STEMI. For these metabolically unhealthy obese younger adults with STEMI, regular exercise and weight reduction are necessary to improve the metabolic state. Because younger adults with STEMI had higher levels of TC, TG, and LDL-C ([Table 2](#T2){ref-type="table"}), it is clear that the use of statin in younger STEMI patients will be beneficial in treating lipid abnormalities.

The younger STEMI patients complained of typical chest pain more frequently, but they experienced angina less frequently before hospitalization. According to the analysis of the initial coronary angiogram, the young age group had a higher frequency of single vessel disease than the old age group. These observations suggested that the proposed mechanism causing AMI in the young age group was sudden interruption of coronary blood flow before preconditioning caused by plaque rupture, followed by rapid progression of atherothrombosis rather than atherosclerosis. Shorter, larger, and fewer number of stents were used in the younger adults, and this indicated that thrombosis generally affected a single, large, and short segment of the coronary artery. On the other hand, the elderly patients experienced severe atherosclerosis leading to multi-vessel disease, LM disease, and systolic dysfunction, which were correlated with poor prognosis.[@B3]

Since typical symptoms were experienced more frequently by younger patients, they visited the emergency room much earlier. The higher level of CK-MB in the younger adults indirectly indicated this finding. Actually, our data showed a shorter symptom-to-door time in young patients than in old patients. Meanwhile, there was no significant difference in door-to-balloon time between younger patients and elderly patients in this study. Consequently, the patients in the young age group may have more chance of reducing the ischemic time. However, unfortunately, the mean door-to-balloon time exceeded 90 minutes in both groups. To improve the prognosis of Korean STEMI patients, the physicians and/or the interventionist must make an effort and should pay attention to the methods that can reduce the door-to-balloon time. In the multivariate logistic regression analysis, we determined the independent predictive factors of one-year MACE in the young age group ([Table 7](#T7){ref-type="table"}). They were multivessel disease, renal insufficiency, and LM complex lesion, but these factors were not statistically different from those in the old age group except for multivessel disease. We could not determine the reason for this discrepancy.

In the present study, we analyzed the clinical outcomes of AMI patients such as the in-hospital outcomes and out-of-hospital outcomes ([Table 5](#T5){ref-type="table"}). As expected, the young age group showed excellent prognosis in terms of in-hospital death and complications, one-month, six-month, and twelve-month MACE. There were significant differences in the incidence of cardiac death and noncardiac death between the two groups; however, the young age group did not have a lower incidence of MI, repeat PCI, and CABG compared to the old age group. Because there were significant differences in the baseline clinical characteristics between the two groups, they exerted an influence on the prognosis. When we performed multivariate Cox regression analyses using all of the affecting variables, the age difference was not important as before ([Table 6](#T6){ref-type="table"}). There was no significant clinical benefit in the young STEMI patients at the one-month and twelve-month follow-up ([Fig. 1](#F1){ref-type="fig"}). We concluded that younger patients should be treated continuously like elderly patients with close follow-up. The elderly patients, regardless of their age, should also be treated aggressively.

Our study had several limitations. First, since our study included only diseased patients, we could not accurately identify the risk factors for AMI in young healthy individuals. Second, the long-term prognosis would be more important in young AMI patients; however, a maximum one-year follow-up data were available in the current study. Third, a randomized prospective study, which shows that intensive medical treatment of younger adults improves the clinical outcomes, is needed.

In conclusion, younger Korean STEMI patients included a higher proportion of males and had higher incidences of smoking, obesity, DL, metabolic syndrome, and family history compared with elderly patients. The young age group had more favorable in-hospital outcomes. However, after adjustment for the potential confounders, the clinical outcomes of patients in the young age group were not superior to those of patients in the old age group at the one-year follow-up. Therefore, younger patients should also consistently receive intensive medical treatment like the old aged patients for preventing the MACE.
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![Adjusted MACE-free survival (A) and death-free survival at 12 months by multivariate Cox regression analyses (B). MACE: major adverse cardiac event, HR: hazard ratio.](kcj-45-275-g001){#F1}

###### Baseline clinical characteristics

![](kcj-45-275-i001)

  ----------------------------------------------------------------------------
                                 Young age group\   Old age group\   p
                                 (n=5281)           (n=4896)         
  ------------------------------ ------------------ ---------------- ---------
  Age (years)                    53±7.8             74.3±6.5         \<0.001

  Sex                                                                

   Male                          4729 (89.5)        2904 (59.3)      \<0.001

   Female                        552 (10.5)         1992 (40.7)      \<0.001

  BMI (kg/m^2^)                  24.8±3.3           23.3±3.6         \<0.001

  Obesity                        2109 (39.9)        1174 (24.0)      \<0.001

  WC (cm)                        87.9±8.6           85.8±23.4        \<0.001

  HC (cm)                        93.8±15.9          91.2±25.9        \<0.001

  Symptom-to-door time (hours)   12±53.2            17.3±132         0.010

  Symptom                        4747 (89.9)        4159 (84.9)      \<0.001

   Chest pain                    4742 (89.8)        4112 (84.0)      \<0.001

   Dyspnea                       1026 (19.4)        1255 (25.6)      \<0.001

   Previous angina               1815 (34.4)        1886 (38.5)      \<0.001

  Risk factor                                                        

   Hypertension                  1950 (36.9)        2720 (55.6)      \<0.001

   Diabetes mellitus             1148 (21.7)        1363 (27.8)      \<0.001

   Smoking                       4084 (77.3)        2311 (47.2)      \<0.001

   Dyslipidemia                  590 (11.2)         377 (7.7)        \<0.001

   Metabolic syndrome            3569 (67.6)        3079 (62.9)      \<0.001

   Family history                580 (11.0)         227 (4.6)        \<0.001

   IHD history                   495 (9.4)          636 (13.0)       \<0.001

   Heart failure                 26 (0.5)           85 (1.7)         \<0.001

   Cerebrovascular disease       164 (3.1)          409 (8.4)        \<0.001

   Peripheral vascular disease   15 (0.3)           43 (0.9)         \<0.001

  Physical findings                                                  

   SBP (mmHg)                    128.5±28.2         125±28.6         \<0.001

   DBP (mmHg)                    80.1±17.7          75.8±16.7        \<0.001

   Heart rate (/min)             76.8±18.6          75.9±20.3        0.013

  Killip class                                                       

   I                             4141 (78.4)        3261 (66.6)      \<0.001

   II-IV                         1140 (21.6)        1635 (33.4)      \<0.001

  ECG findings                                                       

   Sinus rhythm                  4861 (92.0)        4262 (87.1)      \<0.001

   AV block (II/III)             121 (2.3)          181 (3.7)        \<0.001

   AF/AFL                        108 (2.0)          218 (4.5)        \<0.001

   VT/VF                         13 (0.2)           13 (0.3)         0.847
  ----------------------------------------------------------------------------

Data are expressed as number (%) or mean±standard deviation. BMI: body mass index, WC: waist circumference, HC: hip circumference, IHD: ischemic heart disease, SBP: systolic blood pressure, DBP: diastolic blood pressure, ECG: electrocardiogram, AV: atrioventricular, AF: atrial fibrillation, AFL: atrial flutter, VT: ventricular tachycardia, VF: ventricular fibrillation

###### Baseline laboratory and echocardiographic findings
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  -------------------------------------------------------------------------
                              Young age group\   Old age group\   p
                              (n=5281)           (n=4896)         
  --------------------------- ------------------ ---------------- ---------
  Troponin I (ng/mL)          64±179.1           60.6±103.4       0.290

  Troponin T (ng/mL)          7.1±39.4           7.5±34.9         0.755

  CK-MB (ng/mL)               199.3±323.2        171.5±263.7      \<0.001

  Creatinine (mg/dL)          1.1±1.3            1.2±1.5          0.041

  eGFR (mL/min/1.73m^2^)      93.7±13.0          78.5±11.5        \<0.001

  Glucose (mg/dL)             169.7±74.9         173.7±75         0.007

  Total cholesterol (mg/dL)   191.2±43.8         178.3±43.7       \<0.001

  Triglyceride (mg/dL)        145.2±120.7        108.1±85.6       \<0.001

  HDL-cholesterol (mg/dL)     44.7±24.0          45.2±14.3        0.246

  LDL-cholesterol (mg/dL)     122.8±40.7         112.8±37.4       \<0.001

  hs-CRP (mg/dL)              8.1±37.7           10.8±44          0.002

  NT-proBNP (pg/mL)           1001±3381.4        2834.1±5705.5    \<0.001

  LVEF (%)                    52±11.3            49.4±12          \<0.001
  -------------------------------------------------------------------------

Data are expressed as mean±standard deviation. CK-MB: creatine kinase-MB, eGFR: estimated glomerular filtration rate, HDL: high-density lipoprotein, LDL: low-density lipoprotein, hs-CRP: high-sensitivity C-reactive protein, NT-proBNP: N-terminal pro B-type natriuretic peptide, LVEF: left ventricular ejection fraction

###### Treatment strategy, baseline coronary angiographic findings, and procedural characteristics in patients who underwent CAG
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  ------------------------------------------------------------------------------
                                   Young age group\   Old age group\   p
                                   (n=5281)           (n=4896)         
  -------------------------------- ------------------ ---------------- ---------
  Primary PCI                      4321 (81.8)        3977 (81.2)      0.442

  Facilitated PCI                  153 (2.9)          123 (2.5)        0.232

  Thrombolysis                     397 (7.5)          241 (4.9)        \<0.001

  Conservative treatment           382 (7.2)          518 (10.6)       \<0.001

  Door-to-balloon time (min)       106.4±54.3         106.6±52.4       0.847

  Number of involved vessels (%)                                       

   1                               2771 (52.8)        1969 (41.4)      \<0.001

   2                               1496 (28.5)        1495 (31.5)      0.001

   3                               904 (17.2)         1146 (24.1)      \<0.001

   LM complex                      69 (1.3)           130 (2.7)        \<0.001

   LM isolated                     7 (0.1)            12 (0.3)         0.172

  Target lesion location (%)                                           

   LAD                             2874 (54.9)        2387 (50.4)      \<0.001

   LCX                             509 (9.7)          435 (9.2)        0.356

   RCA                             1803 (34.5)        1837 (38.8)      \<0.001

   LM                              46 (0.9)           76 (1.6)         0.001

  ACC/AHA types (%)                                                    

   Type A                          206 (4.3)          169 (3.9)        0.341

   Type B1                         986 (20.6)         722 (16.7)       \<0.001

   Type B2                         1370 (28.6)        1247 (28.8)      0.826

   Type C                          2222 (46.4)        2185 (50.5)      \<0.001

  Pre-procedure TIMI flow 0        2807 (56.2)        2510 (55.1)      0.309

  Post-procedure TIMI flow 3       4612 (93.9)        4047 (90.8)      \<0.001

  Stent type (%)                                                       

   Bare metal stent                381 (7.9)          430 (10.0)       \<0.001

   Paclitaxel-eluting stent        1139 (23.6)        1041 (24.1)      0.536

   Sirolimus-eluting stent         1556 (32.2)        1262 (29.2)      0.002

   Zotarolimus-eluting stent       818 (16.9)         760 (17.6)       0.388

   Everolimus-eluting stent        542 (11.2)         456 (10.6)       0.320

   Other DES                       424 (8.8)          389 (9.0)        0.687

  Stent length (mm)                24.4±6.6           24.7±6.6         0.018

  Stent diameter (mm)              3.5±0.6            3.3±0.6          \<0.001

  Total stents per patient (n)     1.4±0.7            1.5±0.8          0.002

  Multi-vessel PCI                 761 (15.2)         733 (16.3)       0.154

  PCI success rate (%)             5044 (99.0)        4541 (99.0)      0.922
  ------------------------------------------------------------------------------

Data are expressed as number (%) or mean±standard deviation. CAG: coronary angiogram, PCI: percutaneous coronary intervention, LM: left main, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery, ACC/AHA: American College of Cardiology/American Heart Association, TIMI: thrombolysis In myocardial infarction, DES: drug-eluting stent

###### Comparison of the prescribed medications
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  --------------------------------------------------------------------------------
                                     Young age group\   Old age group\   p
                                     (n=5222)           (n=4693)         
  ---------------------------------- ------------------ ---------------- ---------
  Aspirin                            5166 (98.5)        4617 (97.7)      0.003

  Clopidogrel                        5073 (99.7)        4533 (95.9)      0.033

  Cilostazol                         1674 (31.9)        1430 (30.3)      0.074

   Dual anti-platelet therapy        3595 (68.8)        3296 (70.2)      0.134

   Triple anti-platelet therapy      1627 (31.2)        1397 (29.8)      0.134

  Beta-blockers                      4199 (80.1)        3524 (74.6)      \<0.001

  ACE inhibitors                     3611 (68.9)        3021 (63.9)      \<0.001

  Angiotensin II receptor blockers   866 (16.5)         926 (19.6)       \<0.001

  Calcium channel blockers           359 (6.8)          311 (6.6)        0.599

  Statin                             4049 (77.2)        3468 (73.4)      \<0.001

  Nitrate                            2468 (47.1)        2121 (44.9)      0.030

  Nicorandil                         1155 (22)          1062 (22.5)      0.589

  Loop diuretics                     751 (14.3)         1319 (27.9)      \<0.001

  Spironolactone                     367 (7.0)          511 (10.8)       \<0.001

  DM medications                                                         

   Oral hypoglycemic agents          443 (8.4)          356 (7.5)        0.094

   Insulin                           65 (1.2)           58 (1.2)         0.957
  --------------------------------------------------------------------------------

Data are expressed as number (%). ACE: angiotensin-converting enzyme, DM: diabetes mellitus

###### Cumulative clinical outcomes
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  -----------------------------------------------------------------------------
                                  Young age group\   Old age group\   p
                                  (n=5281)           (n=4896)         
  ------------------------------- ------------------ ---------------- ---------
  CCU stay (days)                 3.2±3              3.9±4.1          \<0.001

  In-hospital death (%)           37 (0.7)           171 (3.5)        \<0.001

  In-hospital complications (%)   549 (10.4)         767 (15.7)       \<0.001

   Acute kidney injury            11 (0.2)           44 (0.9)         \<0.001

   Cardiogenic shock              162 (3.1)          293 (6.0)        \<0.001

   Atrial fibrillation            34 (0.6)           65 (1.3)         \<0.001

   Major bleeding                 13 (0.2)           25 (0.5)         0.029

  One-month follow-up (%)         n=4491             n=3988           

   Major adverse cardiac events   79 (1.8)           111 (2.8)        0.028

   Cardiac death                  9 (0.2)            38 (1.0)         \<0.001

   MI                             18 (0.4)           28 (0.7)         0.059

   Repeat PCI                     41 (0.9)           38 (1.0)         0.849

   CABG                           11 (0.2)           7 (0.2)          0.488

   Non-cardiac death              6 (0.1)            21 (0.5)         0.001

  Six-month follow-up (%)         n=3681             n=3410           

   Major adverse cardiac events   246 (6.8)          263 (8.2)        \<0.001

   Cardiac death                  12 (0.3)           65 (2.0)         \<0.001

   MI                             24 (0.7)           33 (1.0)         0.098

   Repeat PCI                     195 (5.4)          153 (4.7)        0.246

   CABG                           11 (0.3)           7 (0.2)          0.490

   Non-cardiac death              12 (0.3)           49 (1.5)         \<0.001

  Twelve-month follow-up (%)      n=3254             n=2847           

   Major adverse cardiac events   327 (10.1)         337 (11.9)       0.025

   Cardiac death                  17 (0.5)           81 (2.9)         \<0.001

   MI                             34 (1.1)           36 (1.3)         0.421

   Repeat PCI                     261 (8.1)          208 (7.3)        0.296

   CABG                           17 (0.5)           15 (0.5)         0.981

   Non-cardiac death              20 (0.6)           66 (2.3)         \<0.001
  -----------------------------------------------------------------------------

Data are expressed as number (%) or mean±standard deviation. CCU: coronary care unit, MI: myocardial infarction, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting

###### Cox regression analyses of age difference (young age group vs. old age group) with one-month and twelve-month MACEs
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  Model                                 One-month MACEs    Twelve-month MACEs                      
  ------------------------------------- ------------------ -------------------- ------------------ ---------
  Unadjusted                            0.94 (0.71-1.25)   0.677                0.77 (0.66-0.89)   0.001
  Adjusted for sex                      0.85 (0.63-1.15)   0.295                0.73 (0.62-0.86)   \<0.001
  Adjusted for selected variables^\*^   0.90 (0.65-1.24)   0.517                0.74 (0.62-0.88)   0.001
  Multivariable adjusted^†^             0.95 (0.60-1.51)   0.828                0.86 (0.68-1.10)   0.233

^\*^The variables of baseline clinical characteristics; sex, BMI, presence of typical symptoms, chest pain and dyspnea, history of previous angina, initial vital signs (systolic blood pressure, diastolic blood pressure, and heart rate), Killip classification on admission, symptom-to-door time, arrhythmia, cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, smoking, family history of coronary heart disease, and previous ischemic heart diseases), cerebrovascular or peripheral arterial diseases, and heart failure. †The variables considered potentially relevant on univariate analyses were included; all of the variables mentioned above as the selected variables, treatment strategy, door-to-balloon time, angiographic findings (number of diseased vessels, lesion location and type), procedural findings (stent type, length and diameter, and number of implanted stents), cardiovascular medications (aspirin, clopidogrel, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, Angiotensin II receptor blockers, statin, nitrate, spironolactone, and diuretics), renal insufficiency (estimated glomerular filtration rate\<60 mL/min/1.73m^2^), and left ventricular dysfunction (left ventricular ejection fraction\<40%). MACE: major adverse cardiac event , CI: confidence interval

###### Multivariate logistic regression analysis for predicting the one-year major adverse cardiac events in patients of the young age and old age groups
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                                  Young age group    Old age group                      
  ------------------------------- ------------------ --------------- ------------------ ---------
  Multivessel disease             1.95 (1.37-2.78)   \<0.001         1.76 (1.20-2.57)   0.004
  Renal insufficiency             3.20 (1.03-9.94)   0.044           0.73 (2.67-1.99)   0.537
  LM complex lesion               2.72 (1.01-7.30)   0.048           1.25 (0.57-2.75)   0.584
  Multivessel revascularization   0.56 (0.34-0.92)   0.023           1.23 0.77-1.97)    0.384
  LV dysfunction (LVEF\<40%)      1.41 (0.88-2.26)   0.155           2.09 (1.39-3.14)   \<0.001
  Diabetes mellitus               1.24 (0.87-1.75)   0.236           1.60 (1.14-2.26)   0.007
  Using drug-eluting stent        0.70 (0.42-1.18)   0.186           0.60 (0.38-0.94)   0.025
  ACE inhibitors                  1.23 (0.78-1.93)   0.368           0.62 (0.41-0.95)   0.027

CI: confidence interval, LM: left main: LV: left ventricular, LVEF: left ventricular ejection fraction, ACE: angiotensin-converting enzyme
